Search

Climate change models often assume similar responses to temperatures across the range of a species, but local adaptation or phenotypic plasticity can lead plants and animals to respond differently to temperature in different parts of their range. To date, there have been few tests of this assumption at the scale of continents, so it is unclear if this is a large-scale problem. Here, we examined the assumption that insect taxa show similar responses to temperature at 96 sites in grassy habitats across North America. We sampled insects with Malaise traps during 2019-2021 (N = 1041 samples) and examined the biomass of insects in relation to temperature and time of season. Our samples mostly contained Diptera (33%), Lepidoptera (19%), Hymenoptera (18%), and Coleoptera (10%). We found strong regional differences in the phenology of insects and their response to temperature, even within the same taxonomic group, habitat type, and time of season. For example, the biomass of nematoceran flies increased across the season in the central part of the continent, but it only showed a small increase in the Northeast and a seasonal decline in the Southeast and West. At a smaller scale, insect biomass at different traps operating on the same days was correlated up to ~75 km apart. Large-scale geographic and phenological variation in insect biomass and abundance has not been studied well, and it is a major source of controversy in previous analyses of insect declines that have aggregated studies from different locations and time periods. Our study illustrates that large-scale predictions about changes in insect populations, and their causes, will need to incorporate regional and taxonomic differences in the response to temperature., (© 2023 The Authors. Ecology published by Wiley Periodicals LLC on behalf of The Ecological Society of America.)

Earthworms in the family Lumbricidae in Alaska, which are known from coastal regions, primarily in south-central and south-eastern Alaska, are thought to be entirely non-native and have been shown to negatively impact previously earthworm-free ecosystems in study regions outside of Alaska. Despite occasional collections by curious citizens, there had not been a standardised earthworm survey performed in Interior Alaska and no published records exist of earthworms species from this region. Mustard extraction was used to sample six locations that differed in elevation, mostly in the College region of Fairbanks, Alaska. Two of the six locations yielded earthworms. There was no relationship between earthworm abundance and elevation ( p = 0.087), although our sample size was small. Our sampling, combined with specimens in the University of Alaska Museum, has documented four exotic species and one presumed native species of lumbricid earthworms in Interior Alaska.

This paper presents the results of a survey of beetles conducted in the vicinity of the archaeological site of Nunalleq, a pre-contact (16 th -17 th century AD) indigenous forager settlement located near the modern Yup'ik village of Quinhagak, in the Yukon-Kuskokwim delta, southwestern Alaska. Records and habitat data are reported for 74 beetle taxa collected in tundra, riparian, aquatic and anthropogenic environments from a region of Alaska that has been poorly studied by entomologists. This includes the first mainland Alaskan record for the byrrhid Simplocaria metallica (Sturm). Beyond improving our knowledge of the local beetle fauna's diversity and ecology, this survey provides the basis for comparisons between modern and sub-fossil beetle assemblages from Nunalleq and Quinhagak.

Fourteen species of Liogluta Thomson are reported from Canada and Alaska. Three of these are described as new to science: Liogluta castoris Klimaszewski & Webster, sp. n.; Liogluta microgranulosa Klimaszewski & Webster, sp. n.; and Liogluta pseudocastoris Klimaszewski & Webster, sp. n. The previously unknown male of Liogluta gigantea Klimaszewski & Langor, Liogluta quadricollis (Casey), Liogluta wickhami (Casey), and female of Liogluta granulosa Lohse are described, and illustrated. Liogluta aloconotoides Lohse is synonymized with Liogluta terminalis (Casey). New provincial and state records are provided for six Liogluta species. A key to species, revised distribution with new provincial records, and new natural history data are provided.

Ethambutol (EMB) is used as a part of drug regimens for treatment of tuberculosis (TB). Susceptibility of Mycobacterium tuberculosis complex (MTBC) isolates to EMB can be discerned by DNA sequencing to detect mutations in the embB gene associated with resistance. US Public Health Laboratories (PHL) primarily use growth-based drug susceptibility test (DST) methods to determine EMB resistance. The Centers for Disease Control and Prevention (CDC) provides a service for molecular detection of drug resistance (MDDR) by DNA sequencing and concurrent growth-based DST using agar proportion. PHL and CDC test results were compared for 211 MTBC samples submitted to CDC from September 2009 through February 2011. Concordance between growth-based DST results from PHL and CDC was 88.2%. A growth-based comparison of 39 samples, where an embB mutation associated with EMB resistance was detected, revealed a higher percentage of EMB resistance by CDC (84.6%) than by PHL (59.0%) which was significant (P value = 0.002). Discordance between all growth-based test results from PHL and CDC was also significant (P value = 0.003). Most discordance was linked to false susceptibility using the BACTEC™ MGIT™ 960 (MGIT) growth-based system. Our analysis supports coalescing growth-based and molecular results for an informed interpretation of potential EMB resistance.

This paper treats 13 species of the subgenus Microdota Mulsant & Rey of Atheta Thomson and 3 species of the genus Clusiota Casey in Canada and Alaska. We report here 4 species new to science, and 3 new provincial records. The following species are new to science: Atheta (Microdota) curtipenis Klimaszewski & Webster, sp. n., Atheta (Microdota) formicaensis Klimaszewski & Webster, sp. n., Atheta (Microdota) macesi Klimaszewski & Webster, sp. n., and Clusiota grandipenis Klimaszewski & Webster, sp. n. The new provincial records are: Atheta (Microdota) pseudosubtilis Klimaszewski & Langor, new to AB, and Atheta (Microdota) subtilis (Scriba), an adventive Palaearctic species new to North America, first reported in LB and NB. The two Clusiota Casey species are reviewed, and their distribution is revised. A female Clusiota impressicollis was discovered in Ontario and is illustrated here for the first time. A key to all Canadian species of the subgenus Microdota and genus Clusiota are provided. Atheta (Microdota) holmbergi Bernhauer and Atheta (Microdota) alesi Klimaszewski & Brunke are transferred here to the subgenus Dimetrota Mulsant & Rey.

Background: Despite the ecological and agricultural significance of bumble bees in Alaska, very little is known and published about this important group at the regional level. The objectives of this study were to provide baseline data on species composition, distribution, seasonal biology, and parasites of the genus Bombus at three major agricultural locations within Alaska: Fairbanks, Delta Junction, and Palmer, to lay the groundwork for future research on bumble bee pollination in Alaska., New Information: A total of 8,250 bumble bees representing 18 species was collected from agricultural settings near Delta Junction, Fairbanks, and Palmer, Alaska in 2009 and 2010. Of the 8,250 specimens, 51% were queens, 32.7% were workers, and 16.2% were males. The species composition and relative abundances varied among sites and years. Delta Junction had the highest relative abundance of bumble bees, representing 51.6% of the specimens collected; the other two locations, Fairbanks and Palmer represented 26.5% and 21.8% of the overall catch respectively. The species collected were: BombusbohemicusSeidl 1837 (= B.ashtoni (Cresson 1864)), B.balteatusDahlbom 1832, B.bifariusCresson 1878, B.centralisCresson 1864, B.cryptarum (Fabricius 1775) (=B.moderatusCresson 1863), B.distinguendusMorawitz 1869, B.flavidusEversmann 1852 (=B.fernaldaeFranklin 1911), B.flavifronsCresson 1863, B.frigidusSmith 1854, B.insularis (Smith 1861), B.jonellus (Kirby 1802), B.melanopygusNylander 1848, B.mixtusCresson 1878, B.neoboreusSladen 1919, B.occidentalisGreene 1858, B.perplexusCresson 1863, B.rufocinctusCresson 1863, and B.sylvicolaKirby 1837. Overall, the most common bumble bees near agricultural lands were B.centralis, B.frigidus, B.jonellus, B.melanopygus, B.mixtus, and B.occidentalis. Species' relative population densities and local diversity were highly variable from year to year. Bombusoccidentalis, believed to be in decline in the Pacific Northwest states, represented 10.4% of the overall specimens collected from the three sites studied. Bumble bees were found to be infected by Nosema and nematodes with infection rates up to 2.1% and 16.7% respectively. Of the eight species infected by parasites, B.occidentalis displayed the highest Nosema infection, while B.centralis was the species with the highest infection of nematodes. To our knowledge this represents the first multi-year study on bumble bees from the main agricultural areas of Alaska to provide baseline data on species composition, distribution, seasonal biology, and parasites of the genus Bombus.

Hemorrhage is the leading cause of death from trauma. Intravenous (IV) fluid resuscitation in these patients may cause hemodilution and secondary hemorrhage. In addition, hypothermia may interfere with coagulation. The purposes of this study were to compare the effectiveness QuikClot Combat Gauze (QCG) to a control group on hemorrhage in a hemodiluted, hypothermic model, and to determine the effects of IV volume resuscitation on rebleeding. This was a prospective, between subjects, experimental design. Yorkshire swine were randomly assigned to two groups: QCG (n = 13) or control (n = 13). The subjects were anesthetized. Hypothermia (temperature of ≤34.0 °C) was induced; 30% of their blood volume was exsanguinated. A 3:1 replacement of Lactated Ringer's was administered to dilute the remaining blood. The femoral artery and vein were transected. After 1 min of uncontrolled hemorrhage, QCG was placed into the wound followed by standard wound packing. The control group underwent the same procedures without QCG. After 5 min of manual pressure, a pressure dressing was applied. Following 30 min, the dressings were removed, and blood loss was calculated. For subjects achieving hemostasis, up to 5 L of IV fluid was administered or until bleeding occurred, which was defined as >2% total blood volume. The QCG had significantly less hemorrhage than the control (QCG = 30 ± 99 mL; control = 404 ± 406 mL) (p = .004). Further, the QCG group was able to tolerate more resuscitation fluid before hemorrhage (QCG = 4615 ± 1386 mL; control = 846 ± 1836) (p = .000).

A redescription with illustrations of the species Lyrosoma pallidum and a key to the Korean species of the family Agyrtidae are provided. New distributional data, including a range extension, of the two Lyrosoma Mannerheim species are presented. Lyrosoma pallidum (Eschscholtz) is recorded for the first time in Korea.

Fluoroquinolone antibiotics are among the most potent second-line drugs used for treatment of multidrug-resistant tuberculosis (MDR TB), and resistance to this class of antibiotics is one criterion for defining extensively drug resistant tuberculosis (XDR TB). Fluoroquinolone resistance in Mycobacterium tuberculosis has been associated with modification of the quinolone resistance determining region (QRDR) of gyrA. Recent studies suggest that amino acid substitutions in gyrB may also play a crucial role in resistance, but functional genetic studies of these mutations in M. tuberculosis are lacking. In this study, we examined twenty six mutations in gyrase genes gyrA (seven) and gyrB (nineteen) to determine the clinical relevance and role of these mutations in fluoroquinolone resistance. Transductants or clinical isolates harboring T80A, T80A+A90G, A90G, G247S and A384V gyrA mutations were susceptible to all fluoroquinolones tested. The A74S mutation conferred low-level resistance to moxifloxacin but susceptibility to ciprofloxacin, levofloxacin and ofloxacin, and the A74S+D94G double mutation conferred cross resistance to all the fluoroquinolones tested. Functional genetic analysis and structural modeling of gyrB suggest that M330I, V340L, R485C, D500A, D533A, A543T, A543V and T546M mutations are not sufficient to confer resistance as determined by agar proportion. Only three mutations, N538D, E540V and R485C+T539N, conferred resistance to all four fluoroquinolones in at least one genetic background. The D500H and D500N mutations conferred resistance only to levofloxacin and ofloxacin while N538K and E540D consistently conferred resistance to moxifloxacin only. Transductants and clinical isolates harboring T539N, T539P or N538T+T546M mutations exhibited low-level resistance to moxifloxacin only but not consistently. These findings indicate that certain mutations in gyrB confer fluoroquinolone resistance, but the level and pattern of resistance varies among the different mutations. The results from this study provide support for the inclusion of the QRDR of gyrB in molecular assays used to detect fluoroquinolone resistance in M. tuberculosis.

The current study describes the development of a unique real-time PCR assay for the detection of mutations conferring drug resistance in Mycobacterium tuberculosis. The rifampicin resistance determinant region (RRDR) of rpoB and specific regions of katG and the inhA promoter were targeted for the detection of rifampin (RIF) and isoniazid (INH) resistance, respectively. Additionally, this assay was multiplexed to discriminate Mycobacterium tuberculosis complex (MTC) strains from nontuberculous Mycobacteria (NTM) strains by targeting the IS6110 insertion element. High-resolution melting (HRM) analysis following real-time PCR was used to identify M. tuberculosis strains containing mutations at the targeted loci, and locked nucleic acid (LNA) probes were used to enhance the detection of strains containing specific single-nucleotide polymorphism (SNP) transversion mutations. This method was used to screen 252 M. tuberculosis clinical isolates, including 154 RIF-resistant strains and 174 INH-resistant strains based on the agar proportion method of drug susceptibility testing (DST). Of the 154 RIF-resistant strains, 148 were also resistant to INH and therefore classified as multidrug resistant (MDR). The assay demonstrated sensitivity and specificity of 91% and 98%, respectively, for the detection of RIF resistance and 87% and 100% for the detection of INH resistance. Overall, this assay showed a sensitivity of 85% and a specificity of 98% for the detection of MDR strains. This method provides a rapid, robust, and inexpensive way to detect the dominant mutations known to confer MDR in M. tuberculosis strains and offers several advantages over current molecular and culture-based techniques.

The TB-Biochip oligonucleotide microarray system is a rapid system to detect mutations associated with rifampin (RIF) resistance in mycobacteria. After optimizing the system with 29 laboratory-generated rifampin-resistant mutants of Mycobacterium tuberculosis, we evaluated the performance of this test using 75 clinical isolates of Mycobacterium tuberculosis. With this small sample set, the TB-Biochip system displayed a sensitivity of 80% and a specificity of 100% relative to conventional drug susceptibility testing results for RIF resistance. For these samples (approximately 50% tested positive), the positive predictive value was 100% and the negative predictive value was 85%. Four of the seven observed discrepancies were attributed to rare and new mutations not represented in the microarray, while three of the strains with discrepant results did not carry mutations in the RIF resistance-determining region. The results of this study confirm the utility of the system for rapid detection of RIF resistance and suggest approaches to increasing its sensitivity.

Ethionamide (ETH) is a structural analog of the antituberculosis drug isoniazid (INH). Both of these drugs target InhA, an enzyme involved in mycolic acid biosynthesis. INH requires catalase-peroxidase (KatG) activation, and mutations in katG are a major INH resistance mechanism. Recently an enzyme (EthA) capable of activating ETH has been identified. We sequenced the entire ethA structural gene of 41 ETH-resistant Mycobacterium tuberculosis isolates. We also sequenced two regions of inhA and all or part of katG. The MICs of ETH and INH were determined in order to associate the mutations identified with a resistance phenotype. Fifteen isolates were found to possess ethA mutations, for all of which the ETH MICs were > or =50 microg/ml. The ethA mutations were all different, previously unreported, and distributed throughout the gene. In eight of the isolates, a missense mutation in the inhA structural gene occurred. The ETH MICs for seven of the InhA mutants were > or =100 microg/ml, and these isolates were also resistant to > or =8 microg of INH per ml. Only a single point mutation in the inhA promoter was identified in 14 isolates. A katG mutation occurred in 15 isolates, for which the INH MICs for all but 1 were > or =32 microg/ml. As expected, we found no association between katG mutation and the level of ETH resistance. Mutations within the ethA and inhA structural genes were associated with relatively high levels of ETH resistance. Approximately 76% of isolates resistant to > or =50 microg of ETH per ml had such mutations.

Mycobacterium tuberculosis complex isolates from cerebrospinal fluid of 67 meningitis patients were obtained from six fever hospitals in Egypt. One M. bovis and 66 M. tuberculosis isolates were identified by PCR-restriction fragment length polymorphism (RFLP) analysis of oxyR. Among the M. tuberculosis isolates, 53 unique strain types (with 3 to 16 copies of IS6110) were found by RFLP analyses. Nine clusters (eight with two isolates each and one with six isolates) were also found. Thirty-six spoligotypes, including at least 10 that have been previously reported from other countries, were also observed. Forty-one (62.1%) of the isolates were in spoligotype clusters, and 22 (33%) of the isolates were in RFLP clusters. Fifty-one of the isolates were susceptible in vitro to all of the antituberculosis drugs tested, 11 were monoresistant to capreomycin, rifampin, isoniazid (INH), pyrazinamide, or streptomycin (STR), 4 were resistant to STR and INH, and 1 was resistant to STR, INH, and ethambutol.

Mycobacterium abscessus and Mycobacterium chelonae are two closely related species that are often not distinguished by clinical laboratories despite the fact they cause diseases requiring different treatment regimens. Multilocus enzyme electrophoresis, PCR-restriction fragment length polymorphism analysis of the 65-kDa heat shock protein gene, biochemical tests, and high-performance liquid chromatography of mycolic acids were used to identify 75 isolates as either M. abscessus or M. chelonae that were originally submitted for drug susceptibility testing. Only 36 of these isolates were submitted with an identification at the species level. Using the above methods, 46 of the isolates were found to be M. abscessus and 29 were identified as M. chelonae. Eight isolates originally submitted as M. chelonae were identified as M. abscessus, and one isolate submitted as M. abscessus was found to be M. chelonae. The four identification methods were in agreement in identifying 74 of the 75 isolates. In drug susceptibility testing, all isolates of M. abscessus exhibited resistance to tobramycin (MIC of 8 to > or =16 microg/ml), while all isolates of M. chelonae were susceptible to this drug (MIC of < or = 4 microg/ml). The results suggest that once an identification method is selected, clinical laboratories should be able to easily identify isolates of M. abscessus and M. chelonae.

We examined the correlation of mutations in the pyrazinamidase (PZase) gene (pncA) with the pyrazinamide (PZA) resistance phenotype with 60 Mycobacterium tuberculosis isolates. PZase activity was determined by the method of Wayne (L. G. Wayne, Am. Rev. Respir. Dis. 109:147-151, 1974), and the entire pncA nucleotide sequence, including the 74 bp upstream of the start codon, was determined. PZA susceptibility testing was performed by the method of proportions on modified Middlebrook and Cohn 7H10 medium. The PZA MICs were > or =100 microg/ml for 37 isolates, 34 of which had alterations in the pncA gene. These mutations included missense substitutions for 24 isolates, nonsense substitutions for 3 isolates, frameshifts by deletion for 4 isolates, a three-codon insertion for 1 isolate, and putative regulatory mutations for 2 isolates. Among 21 isolates for which PZA MICs were <100 microg/ml, 3 had the same mutation (Thr47-->Ala) and 18 had the wild-type sequence. For the three Thr47-->Ala mutants PZA MICs were 12.5 microg/ml by the method of proportions on 7H10 agar; two of these were resistant to 100 microg of PZA per ml and the third was resistant to 800 microg of PZA per ml by the BACTEC method. In all, 30 different pncA mutations were found among the 37 pncA mutants. No PZase activity was detected in 35 of 37 strains that were resistant to > or =100 microg of PZA per ml or in 34 of 37 pncA mutants. Reduced PZase activity was found in the three mutants with the Thr47-->Ala mutation. This study demonstrates that mutations in the pncA gene may serve as a reliable indicator of resistance to > or =100 microg of PZA per ml.

Objective: To compare the clinical efficacy, effect on serum C-reactive protein (CRP), serum amyloid A (SAA), and plasma interleukin-6 (IL-6) levels, and safety of tenidap with a combination of hydroxychloroquine-plus-piroxicam, and piroxicam alone, in the treatment of rheumatoid arthritis (RA) patients., Methods: A double-blind, randomized, multicenter study in which patients with active RA were treated with tenidap 120 mg/day, hydroxychloroquine 400 mg/day and piroxicam 20 mg/day, or piroxicam alone 20 mg/day, for 24 weeks., Results: At weeks 12 and 24, tenidap produced greater improvements than piroxicam based on 5 primary efficacy parameters; this improvement showed statistical significance in 4 of the 5 measures at week 12, and in 3 of the 5 measures at week 24. Clinical improvements in the hydroxychloroquine-plus-piroxicam-treated with tenidap. Compared with piroxicam, tenidap was associated with significantly greater reductions in serum CRP concentrations at 4, 12, and 24 weeks, and significantly greater reductions in SAA concentrations at weeks 12 and 24. The decrease in SAA concentrations was also significantly greater at weeks 4 and 24 in the tenidap-treated group than in the hydroxychloroquine-plus-piroxicam-treated group. Significant reductions in plasma IL-6 levels were observed at weeks 4, 12, and 24 within the tenidap group, and at week 24 within the hydroxychloroquine-plus-piroxicam-treated group. The overall occurrence of side effects, including gastrointestinal side effects, was similar in all 3 treatment groups. A small proportion of tenidap-treated patients (6.4%) manifested mild, nonprogressive, reversible proteinuria of presumed renal proximal tubular origin, and 3-4% of patients had elevated transaminase levels., Conclusion: In the treatment of patients with RA, tenidap is as effective as the combination of hydroxychloroquine-plus-piroxicam, and is more effective than piroxicam alone; moreover, tenidap's safety profile is comparable to that observed with piroxicam alone, and with hydroxychloroquine-plus-piroxicam. The clinical response observed in this study, as well as the prompt decreases in acute-phase protein levels of CRP and SAA, and in plasma IL-6 levels, suggest that tenidap represents a new type of antiarthritic medication, with properties similar to, but not identical to, a therapeutic combination of a nonsteroidal antiinflammatory drug with disease-modifying antirheumatic drugs.

There was produced with Ery. rhusiopathiae a rheumatoid-like arthritis in swine, which passed successively through acute, sub-acute and chronic stages. This was typically a non-suppurative proliferative change with concurrent changes in the joint fluid. The arthritis was shown to persist even though the initial inciting agent could not be isolated from the advanced cases of chronic polyarthritis. This strongly suggests that the pathological process responsible for this arthritis can become autonomic and probably is related to a state of hypersensitivity. The cellular changes observed in the synovial fluid did not differ markedly from those of rheumatoid arthritis in man. Synovial fluid mucinous changes were apparent in the decreased viscosity observed grossly. Definite changes in the character of the precipitate produced by acetic acid treatment of the fluid were also observed.

A five and one-half year old deer (Odocoileus virginianus) developed an ankylosing periarticular hypertrophic arthritis due to a coagulase positive staphylococcus infection. Complete encasement of the tibio-tarsal (hock) joints with a hypertrophic, and porous osseous mass had occurred with complete loss of articular cartilage. The pathologic alterations of the tissues are compared to those occurring in swine due to Erysipelothrix insidiosa infection which produces a rheumatoid-like arthritis.